Hal M Hoffman
University of California
6 Papers
43 Citations
Hal M Hoffman is an academic researcher from University of California. The author has contributed to research in topics: Familial Cold Autoinflammatory Syndrome & Interleukin 1 receptor antagonist. The author has an hindex of 5, co-authored 6 publications. Previous affiliations of Hal M Hoffman include University of Paris-Sud.
Chat about Author
Papers
In silico validation of the Autoinflammatory Disease Damage Index.
Nienke M. Ter Haar,Amber Laetitia Justine Van Delft,Kim V. Annink,Henk F. van Stel,Sulaiman M. Al-Mayouf,Gayane Amaryan,Jordi Anton,Karyl S. Barron,Susanne M. Benseler,Paul A. Brogan,Luca Cantarini,Marco Cattalini,Alexis Virgil Cochino,Fabrizio De Benedetti,Fatma Dedeoglu,Adriana Almeida de Jesus,Erkan Demirkaya,Erkan Demirkaya,Pavla Dolezalova,Karen L. Durrant,Giovanna Fabio,Romina Gallizzi,Raphaela Goldbach-Mansky,Eric Hachulla,Véronique Hentgen,Troels Herlin,Michael Hofer,Hal M Hoffman,Antonella Insalaco,Annette Jansson,Tilmann Kallinich,Isabelle Koné-Paut,Anna Kozlova,Jasmin B Kuemmerle-Deschner,Helen J. Lachmann,Ronald M. Laxer,Alberto Martini,Susan Nielsen,Irina Nikishina,Amanda K. Ombrello,Seza Ozen,Efimia Papadopoulou-Alataki,Pierre Quartier,Donato Rigante,Ricardo Russo,Anna Simon,Maria Trachana,Yosef Uziel,Angelo Ravelli,Grant S. Schulert,Marco Gattorno,Joost Frenkel +51 more
TL;DR: The Autoinflammatory Disease Damage Index is a reliable and valid instrument to quantify damage in individual patients and can be used to compare disease outcomes in clinical studies.
34
•Journal Article
Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.
Samy Metyas,Hal M Hoffman +1 more
TL;DR: The successful longterm treatment of a patient with FCAS with anakinra, an interleukin 1 receptor antagonist (IL-1Ra), suggests that IL-1 is an important mediator of these inflammatory diseases.
28
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
F De Benedetti,J. Anton,Eldad Ben-Chetrit,Inmaculada Calvo,J Frenkel,Marco Gattorno,Hal M Hoffman,Ozgur Kasapcopur,I Kone-Paut,H Lachmann,Michel Moutschen,S Ozen,Pierre Quartier,Anna Simon,Andrew Zeft,Karine Lheritier,A. Speziale,Guido Junge +17 more
- 01 Apr 2017
TL;DR: The safety and effectiveness of Canakinumab in patients with periodic fever syndromes (colchicine-resistant fmf, hids/mkd and traps): results from a phase 3, pivotal, umbrella trial F. De Benedetti Pediatric Rheumatology 2017, 15(Suppl 1):O1 is presented.
9
Association between celiac sprue and cryopyrin associated autoinflammatory disorders: a case report
TL;DR: A young child with histologically diagnosed celiac disease and a cryopyrinopathy is reported, with signs of arthritis seen in both conditions.
Erratum: IL-1 family nomenclature (Nature Immunology (2010) 11 (973))
Charles A. Dinarello,William P. Arend,John E. Sims,Dirk E. Smith,Hal Blumberg,Luke A. J. O'Neill,Raphaela Goldbach-Mansky,Theresa T. Pizarro,Hal M Hoffman,Philip Bufler,Marcel F. Nold,Pietro Ghezzi,Alberto Mantovani,Cecilia Garlanda,Diana Boraschi,Anna Rubartelli,Mihai G. Netea,Jos W. M. van der Meer,Leo A. B. Joosten,Thomas Mandrup-Poulsen,Marc Y. Donath,Eli C. Lewis,Josef Pfeilschifter,Michael U. Martin,Michael Kracht,H. Muehl,Daniela Novick,Miodrag L. Lukic,Bruno Conti,Alan M. Solinger,Kelk Peyman,Frank L. van de Veerdonk,Chiristopher Gabel +32 more
TL;DR: In the version of this article initially published, the author name Peyman Kelk was inverted and the error has been corrected in the HTML and PDF versions of the article.